Breaking News

Oramed Pharmaceuticals to Spin Off Its Protein Oral Delivery Technology

Announces joint venture with Hefei Tianhui Biotech Co. Ltd. called OraTech Pharmaceuticals Inc.

Author Image

By: Charlie Sternberg

Associate Editor

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, has entered into definitive agreements to spin off its Protein Oral Delivery (POD) technology into a newly formed joint venture, OraTech Pharmaceuticals Inc., with Hefei Tianhui Biotech Co., Ltd. (HTIT). This transaction is designed to accelerate the development and commercialization of Oramed’s ORMD-0801 oral insulin and other POD-based innovative oral drug d...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters